Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.
The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.
Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.
Company Details
- Employees
- 11
- Founded
- 2021
- Address
- Via Nizza, 52, Turin,piedmont 10126,italy
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Turin, Piedmont
Resalis Therapeutics Questions
Resalis Therapeutics's website is http://www.resalistherapeutics.com
Resalis Therapeutics's LinkedIn profile is https://it.linkedin.com/company/resalistherapeutics
Resalis Therapeutics has
11 employees.
View email and phone details for 11
employees at Resalis Therapeutics.
Resalis Therapeutics's industry is
Biotechnology Research
Resalis Therapeutics's top competitors are
Prebiomics,
Aavantgarde,
Alia Therapeutics,
Kither Biotech,
Altheia Science,
Iama Therapeutics,
Sibylla Biotech,
Genenta Science (Nasdaq: Gnta),
Cellply,
Claris Ventures.
Resalis Therapeutics's categories are Biotechnology Research
Resalis Therapeutics's founding year is 2021
